VERTEX PHARMACEUTICALS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
VERTEX PHARMACEUTICALS INC. - More news...
VERTEX PHARMACEUTICALS INC. - More news...
- Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
- Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
- Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA
- Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
- Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
- Vertex to Participate in Upcoming Investor Conferences
- Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
- Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
- Vertex Reports Third Quarter 2022 Financial Results
- Vertex to Announce Third Quarter 2022 Financial Results on October 27
- Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
- Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
- Vertex Appoints Jonathan Biller as Chief Legal Officer
- Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
- Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9
- Vertex Reports Second Quarter 2022 Financial Results
- Vertex Advances VX-548 in Acute and Neuropathic Pain
- Vertex to Announce Second Quarter 2022 Financial Results on August 4
- Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes
- Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
- Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
- Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
- Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
- Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
- Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions
- Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
- Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vertex Pharmaceuticals Incorporated - VRTX
- INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Vertex Pharmaceuticals Incorporated with Losses of $100,000 to Contact the Firm
- INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Vertex Pharmaceuticals Incorporated with Losses of $100,000 to Contact the Firm